- international editions:
.
.
the total amount paid out in life claims was £129.4m, with £13.46m paid in terminal illness claims.
.
.
. following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv).
.
. or water. symptoms include fatigue, low appetite, stomach pain, nausea, and jaundice.